HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro

G. Abou-Mohamed, Andreas Papapetropoulos, D. Ulrich, J. D. Catravas, R. R. Tuttle, R. W. Caldwell

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

α-Melanocyte stimulating hormone has been shown to prevent endotoxin shock. A heptapeptide analog (HP-22B) has recently been synthesized and shown to be an even more potent protective agent. Because the hypotensive and toxic actions of lipopolysaccharide (LPS) appear to involve the induction of type II nitric oxide synthase (iNOS), we have examined the actions of HP-228 on nitric oxide production using an endotoxemia model in conscious rats given E. coli LPS (5 mg/kg i.v.) and monitored for 6 h. A group of rats received HP- 228 (30 μg/kg) 30 min before LPS. Using nitro L-arginine methyl ester- sensitive cGMP production as an estimate of nitric oxide synthase activity in aortic segments, ex vivo, we determined that LPS increases iNOS activity and that HP-22B pretreatment markedly reduces this response. Additionally, the rate of conversion of 3[H]-arginine to 3[H]-citrulline was significantly reduced in lung homogenates from HP-228-treated rats. HP-228 did not alter the activity of the constitutive nitric oxide synthase in aortic rings or in cerebella. In isolated rat aortic smooth muscle cells, LPS or interleukin- 1β caused prominent rises in nitric oxide generated by iNOS. HP-228 did not antagonize the effect of these inducing agents. However, in these cells, plasma obtained from rats 1 h after administration of HP-228 prevented the induction of iNOS by both LPS and interleukin-1β. In conclusion, HP-228 prevents the in vivo induction of nitric oxide synthase by LPS. It does not appear to directly prevent these actions of LPS and interleukin-1β, which suggests that a metabolite of HP-228 and/or secondary mediator (s) may be involved.

Original languageEnglish (US)
Pages (from-to)584-591
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume275
Issue number2
StatePublished - Dec 1 1995
Externally publishedYes

Fingerprint

Nitric Oxide Synthase
Lipopolysaccharides
Peptides
Nitric Oxide Synthase Type II
Interleukin-1
Nitric Oxide
Melanocyte-Stimulating Hormones
Toxic Actions
Protective Agents
Citrulline
Endotoxemia
HP 228
In Vitro Techniques
Plasma Cells
Endotoxins
Cerebellum
Smooth Muscle Myocytes
Arginine
Shock
Escherichia coli

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. / Abou-Mohamed, G.; Papapetropoulos, Andreas; Ulrich, D.; Catravas, J. D.; Tuttle, R. R.; Caldwell, R. W.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 275, No. 2, 01.12.1995, p. 584-591.

Research output: Contribution to journalArticle

Abou-Mohamed, G. ; Papapetropoulos, Andreas ; Ulrich, D. ; Catravas, J. D. ; Tuttle, R. R. ; Caldwell, R. W. / HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. In: Journal of Pharmacology and Experimental Therapeutics. 1995 ; Vol. 275, No. 2. pp. 584-591.
@article{106511a754384fcf8fbdc1ae6cb70acb,
title = "HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro",
abstract = "α-Melanocyte stimulating hormone has been shown to prevent endotoxin shock. A heptapeptide analog (HP-22B) has recently been synthesized and shown to be an even more potent protective agent. Because the hypotensive and toxic actions of lipopolysaccharide (LPS) appear to involve the induction of type II nitric oxide synthase (iNOS), we have examined the actions of HP-228 on nitric oxide production using an endotoxemia model in conscious rats given E. coli LPS (5 mg/kg i.v.) and monitored for 6 h. A group of rats received HP- 228 (30 μg/kg) 30 min before LPS. Using nitro L-arginine methyl ester- sensitive cGMP production as an estimate of nitric oxide synthase activity in aortic segments, ex vivo, we determined that LPS increases iNOS activity and that HP-22B pretreatment markedly reduces this response. Additionally, the rate of conversion of 3[H]-arginine to 3[H]-citrulline was significantly reduced in lung homogenates from HP-228-treated rats. HP-228 did not alter the activity of the constitutive nitric oxide synthase in aortic rings or in cerebella. In isolated rat aortic smooth muscle cells, LPS or interleukin- 1β caused prominent rises in nitric oxide generated by iNOS. HP-228 did not antagonize the effect of these inducing agents. However, in these cells, plasma obtained from rats 1 h after administration of HP-228 prevented the induction of iNOS by both LPS and interleukin-1β. In conclusion, HP-228 prevents the in vivo induction of nitric oxide synthase by LPS. It does not appear to directly prevent these actions of LPS and interleukin-1β, which suggests that a metabolite of HP-228 and/or secondary mediator (s) may be involved.",
author = "G. Abou-Mohamed and Andreas Papapetropoulos and D. Ulrich and Catravas, {J. D.} and Tuttle, {R. R.} and Caldwell, {R. W.}",
year = "1995",
month = "12",
day = "1",
language = "English (US)",
volume = "275",
pages = "584--591",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro

AU - Abou-Mohamed, G.

AU - Papapetropoulos, Andreas

AU - Ulrich, D.

AU - Catravas, J. D.

AU - Tuttle, R. R.

AU - Caldwell, R. W.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - α-Melanocyte stimulating hormone has been shown to prevent endotoxin shock. A heptapeptide analog (HP-22B) has recently been synthesized and shown to be an even more potent protective agent. Because the hypotensive and toxic actions of lipopolysaccharide (LPS) appear to involve the induction of type II nitric oxide synthase (iNOS), we have examined the actions of HP-228 on nitric oxide production using an endotoxemia model in conscious rats given E. coli LPS (5 mg/kg i.v.) and monitored for 6 h. A group of rats received HP- 228 (30 μg/kg) 30 min before LPS. Using nitro L-arginine methyl ester- sensitive cGMP production as an estimate of nitric oxide synthase activity in aortic segments, ex vivo, we determined that LPS increases iNOS activity and that HP-22B pretreatment markedly reduces this response. Additionally, the rate of conversion of 3[H]-arginine to 3[H]-citrulline was significantly reduced in lung homogenates from HP-228-treated rats. HP-228 did not alter the activity of the constitutive nitric oxide synthase in aortic rings or in cerebella. In isolated rat aortic smooth muscle cells, LPS or interleukin- 1β caused prominent rises in nitric oxide generated by iNOS. HP-228 did not antagonize the effect of these inducing agents. However, in these cells, plasma obtained from rats 1 h after administration of HP-228 prevented the induction of iNOS by both LPS and interleukin-1β. In conclusion, HP-228 prevents the in vivo induction of nitric oxide synthase by LPS. It does not appear to directly prevent these actions of LPS and interleukin-1β, which suggests that a metabolite of HP-228 and/or secondary mediator (s) may be involved.

AB - α-Melanocyte stimulating hormone has been shown to prevent endotoxin shock. A heptapeptide analog (HP-22B) has recently been synthesized and shown to be an even more potent protective agent. Because the hypotensive and toxic actions of lipopolysaccharide (LPS) appear to involve the induction of type II nitric oxide synthase (iNOS), we have examined the actions of HP-228 on nitric oxide production using an endotoxemia model in conscious rats given E. coli LPS (5 mg/kg i.v.) and monitored for 6 h. A group of rats received HP- 228 (30 μg/kg) 30 min before LPS. Using nitro L-arginine methyl ester- sensitive cGMP production as an estimate of nitric oxide synthase activity in aortic segments, ex vivo, we determined that LPS increases iNOS activity and that HP-22B pretreatment markedly reduces this response. Additionally, the rate of conversion of 3[H]-arginine to 3[H]-citrulline was significantly reduced in lung homogenates from HP-228-treated rats. HP-228 did not alter the activity of the constitutive nitric oxide synthase in aortic rings or in cerebella. In isolated rat aortic smooth muscle cells, LPS or interleukin- 1β caused prominent rises in nitric oxide generated by iNOS. HP-228 did not antagonize the effect of these inducing agents. However, in these cells, plasma obtained from rats 1 h after administration of HP-228 prevented the induction of iNOS by both LPS and interleukin-1β. In conclusion, HP-228 prevents the in vivo induction of nitric oxide synthase by LPS. It does not appear to directly prevent these actions of LPS and interleukin-1β, which suggests that a metabolite of HP-228 and/or secondary mediator (s) may be involved.

UR - http://www.scopus.com/inward/record.url?scp=0029584296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029584296&partnerID=8YFLogxK

M3 - Article

VL - 275

SP - 584

EP - 591

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -